Valuation Comps
BLUEPRINT — every business spun up from the factory inherits this template. Instance data lives in .invisible/ventures/{slug}/finance/. Never hardcode a business name, currency, or specific comparable in this file.
Founders either over-ask (kill the round) or under-ask (leave money on the table). Valuation is the most contested number in any raise. This template triangulates from three sources: public comps, precedent transactions, and DCF cross-check. The goal is a defensible range, not a single number.
Business Alignment
| Question | Answer |
|---|---|
| Venture name | [instance: name] |
| Raise stage | pre-seed / seed / Series A / token / M&A |
| Target valuation range | $X – $Y |
| Conviction | HIGH / MEDIUM / LOW / NONE |
| Who owns this analysis? | [valuation-analyst agent / fractional CFO] |
Three Triangulation Sources
No single method is right. Cross-check across three.
| Method | What it measures | When it leads |
|---|---|---|
| Public comps | What the market pays for similar companies today | Stage has public equivalents |
| Precedent transactions | What acquirers actually paid | Late-stage, M&A context |
| DCF cross-check | What the business is worth based on future cash flows | Any stage — keeps the other two honest |
Public Comps
List 5–10 public companies in the same business model. Not the same industry — the same shape of revenue.
| Company | Revenue | Revenue multiple | Growth rate | Gross margin | Why comparable |
|---|---|---|---|---|---|
| [name] | $ | x | % | % | [model match reason] |
Trim the tails: drop the highest and lowest 20% to get a defensible multiple range.
Precedent Transactions
Last 24 months. Acquisitions of companies at similar stage and model.
| Target | Acquirer | Deal size | Target revenue | Multiple paid | Date |
|---|
Read the story: why did the acquirer pay this multiple? Distress sale, strategic fit, competitive bidding war, desperate buyer? The multiple carries context.
DCF Cross-Check
Build a 5-year projection with terminal value. Discount at stage-appropriate rate.
| Input | Range | Notes |
|---|---|---|
| 5-year revenue forecast | [from financial-modeler] | Reconcile to pitch deck |
| Free cash flow margin | [range] | Exit margin assumption |
| Terminal growth rate | 2–3% | Not the growth rate — the terminal |
| Discount rate | 15–30% | Stage-adjusted (early stage higher) |
| Terminal multiple | 10–15x FCF | Or industry median |
DCF trap: wide ranges in early-stage assumptions produce wide valuations. Use DCF to sanity-check the other two methods, not to set price.
Pre/Post-Money Bridge
| Line | $ |
|---|---|
| Pre-money valuation | |
| New investment | |
| Post-money valuation | |
| New investor ownership % | |
| Existing shareholders ownership % | |
| Option pool expansion % | |
| Effective founder dilution |
409A (If Applicable)
For US-registered companies issuing employee options. Separate from fundraising valuation — typically 20–40% lower, reflecting common-stock discount.
| Parameter | Notes |
|---|---|
| 409A provider | [third party] |
| Fair market value of common | Lower than preferred |
| Update frequency | Every 12 months or after material event |
| Material events | Primary raise, acquisition offer, major customer loss |
Sanity Checks
Before stating a number:
- Three methods triangulate to an overlapping range
- The bottom of the range still lets founders build the company (not forced to take a down round at plan)
- The top of the range has real comparable support (not aspirational)
- The multiple reflects growth rate — 30% growth ≠ 300% growth valuation
- Counter-thesis stated: what would make this worth half?
Receipt
On completion, valuation-analyst writes a receipt to .invisible/context/receipts/ with:
factory_instance_id= parent factorybusiness_id= this venture slugphase=financetask_id=finance.5- Primary artefact =
.invisible/ventures/{slug}/finance/valuation.md
Context
- Cap Table — dilution math at the chosen valuation
- Unit Economics · Cash Flow · ROI Analysis — DCF inputs
- Pitch Deck — where the number gets defended
- Investor Map — who agrees with this range
Questions
- If all three methods disagree, which do you trust — and why?
- What's the lowest valuation you'd accept, and what would you give up to protect the higher number?
- Which comparable in your list is the one investors will push back on? Have you rehearsed the answer?